Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (10051)	12/12/2008 6:21:20 PM
From: scaram(o)uche	2 Recommendations Read Replies (1) of 10345

I've given out the same award for years, except that it was called the "Galton Award" before Feuerstein threw a history-constrained perspective at things. :-) Bruce Galton was CEO of Cistron Biotechnologies when they accepted cash as settlement, rather than Immunex shares, after Cistron won an IL-1-related patent dispute. Galton then used the cash to "develop" a diagnostic for periodontal disease. Immunex went on to develop Enbrel and was purchased by Amgen. Amgen shares did their Amgen thing. Feuerstein can rename the Award. No problem. But there's bad, and then there's Galton bad. edit: to answer your question.... I think that Martin is an outstanding nominee, re. BAP expectations. But I still consider Tysabri to be perhaps the ultimate application, thus far, of biology to medicine. PML sucks, and it's awful learning about quiescent viruses in the fashion that we've been learning of them. But Tysabri was elegantly conceived, and I'm a fan (not shareholder, thank the powers that be!) of Elan. So...... I'd say that Martin might look better, if he wasn't snake-bit. :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next